Literature DB >> 12482045

Dexamethasone pulse therapy in pemphigus.

G G Tóth1, J B van de Meer, M F Jonkman.   

Abstract

Pulse therapy with high-dose glucocorticoids was introduced 20 years ago as a treatment modality for autoimmune disease and transplant rejection. The most popular dermatological indication for pulse therapy is severe pemphigus. We reviewed the sequelae of 14 patients with pemphigus who were treated by pulse therapy. Seven of them reached complete remission, although three of them needed a new pulse course due to disease flare-up. Adverse events were minor and confined to 60% of all patients: temporary facial flushing during pulse administration, sleep disturbances during the first night after pulse administration, and mood changes occurred during the week of pulse therapy. The study showed the possibility of oral instead of an intravenous mute of dexamethasone pulse administration, which makes double-blind placebo-controlled trials ethically feasible. Fifty per cent of the patients reached complete remission. This retrospective study does not allow claims on the steroid-sparing effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482045     DOI: 10.1046/j.1468-3083.2002.00413.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  3 in total

Review 1.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

2.  Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report.

Authors:  Giovanni Angelini; Domenico Bonamonte; Alberta Lucchese; Gianfranco Favia; Rosario Serpico; Abraham Mittelman; Simone Simone; Animesh A Sinha; Darja Kanduc
Journal:  J Transl Med       Date:  2006-10-24       Impact factor: 5.531

3.  Successful treatment of drug reaction with eosinophilia and systemic symptoms syndrome relapse with oral pulsed dexamethasone.

Authors:  Claire-Audrey Y Bayan; Adriana Lopez; Natalia M Fontecilla; Larisa J Geskin
Journal:  JAAD Case Rep       Date:  2018-10-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.